Accumulating pieces of evidence report that sotorasib is becoming resistant among NSCLC, pancreatic ductal adenocarcinoma, and colorectal adenocarcinoma patients bearing KRAS G12C mutation and even resulting in hepatotoxicity (31, 32). Here, KRAS is linked to pancreatic ductal adenocarcinoma.